Shares of BioDelivery Sciences International Inc. (NASDAQ:BDSI) were up 13.9% on Tuesday . The stock traded as high as $3.10 and last traded at $2.86, with a volume of 3,156,108 shares trading hands. The stock had previously closed at $2.51.

Several analysts have recently weighed in on BDSI shares. FBR & Co reiterated a “positive” rating and issued a $12.00 price objective on shares of BioDelivery Sciences International in a research note on Tuesday, March 29th. Roth Capital reiterated a “buy” rating on shares of BioDelivery Sciences International in a research note on Monday, March 28th. Zacks Investment Research lowered shares of BioDelivery Sciences International from a “hold” rating to a “strong sell” rating in a research note on Friday, May 6th. Cantor Fitzgerald lowered shares of BioDelivery Sciences International from a “buy” rating to a “hold” rating and decreased their price target for the company from $9.00 to $5.00 in a research note on Wednesday, May 11th. Finally, Piper Jaffray Cos. restated an “overweight” rating and set a $4.00 price target (down previously from $6.00) on shares of BioDelivery Sciences International in a research note on Thursday, May 12th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $8.38.

The stock’s market cap is $138.81 million. The stock has a 50-day moving average price of $2.42 and a 200-day moving average price of $3.22.

BioDelivery Sciences International (NASDAQ:BDSI) last announced its earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by $0.01. The business earned $3 million during the quarter, compared to analyst estimates of $2.96 million. During the same quarter last year, the firm earned ($0.16) earnings per share. The business’s revenue was down 77.1% on a year-over-year basis. On average, analysts anticipate that BioDelivery Sciences International Inc. will post ($1.19) earnings per share for the current fiscal year.

A number of hedge funds and institutional investors have recently made changes to their positions in BDSI. Russell Frank Co boosted its position in shares of BioDelivery Sciences International by 57.5% in the fourth quarter. Russell Frank Co now owns 1,080,051 shares of the specialty pharmaceutical company’s stock valued at $5,151,000 after buying an additional 394,272 shares during the last quarter. Sei Investments Co. boosted its position in BioDelivery Sciences International by 240.1% in the fourth quarter. Sei Investments Co. now owns 330,789 shares of the specialty pharmaceutical company’s stock worth $1,584,000 after buying an additional 233,519 shares during the last quarter. Bank of Montreal Can boosted its position in BioDelivery Sciences International by 3.6% in the fourth quarter. Bank of Montreal Can now owns 829,056 shares of the specialty pharmaceutical company’s stock worth $3,971,000 after buying an additional 28,838 shares during the last quarter. Royce & Associates LLC boosted its position in BioDelivery Sciences International by 6.2% in the fourth quarter. Royce & Associates LLC now owns 1,487,800 shares of the specialty pharmaceutical company’s stock worth $7,127,000 after buying an additional 87,200 shares during the last quarter. Finally, Turner Investments L.P. boosted its position in BioDelivery Sciences International by 55.4% in the fourth quarter. Turner Investments L.P. now owns 900,830 shares of the specialty pharmaceutical company’s stock worth $4,315,000 after buying an additional 321,290 shares during the last quarter.

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.